Since its founding in 2007, MRA has awarded more than $101 million for 266 research programs with the potential to make significant, near-term clinical impact in melanoma prevention, diagnosis, staging, and treatment. The following are new grants issued in 2018 in response to three different funding opportunities:

  • Special funding initiative focused on acral melanoma
  • MRA joint grant making partnership with the American Cancer Society (ACS) to address adverse events related to checkpoint immunotherapy
  • MRA’s annual request for proposals

A complete list of all MRA grantees, along with grant abstracts, can be found at